New Liquid Biopsy for Lung Cancer Has High Detection Rate
Delfi Diagnostics’s lung cancer screening technology, which analyzes genome-wide cell-free DNA fragmentation profiles, detected 90% of cases.
Read MorePosted by Chris Wolski | Aug 20, 2021 | Lung Cancer |
Delfi Diagnostics’s lung cancer screening technology, which analyzes genome-wide cell-free DNA fragmentation profiles, detected 90% of cases.
Read MorePosted by Melanie Hamilton-Basich | May 24, 2021 | Lung Cancer |
The new findings show the Percepta Nasal Swab, a first-of-its-kind genomic test, accurately classifies lung cancer risk in current or former smokers with lung nodules so that those with benign nodules may safely avoid unnecessary additional procedures.
Read MorePosted by Laurie Bonner | Jan 27, 2021 | Lung Cancer, Molecular Diagnostics |
Study to focus on using saliva in the analysis of cell-free circulating tumor DNA to accurately and noninvasively detect non-small cell lung cancer.
Read MorePosted by Melanie Hamilton-Basich | Nov 17, 2020 | Flow Cytometry, Lung Cancer |
The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Read MorePosted by Melanie Hamilton-Basich | Sep 14, 2020 | Lung Cancer, Molecular Diagnostics |
Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read More